CClinicalTrials.gg
RecruitingNCT07843277Updated Sep 28, 2026

Implementation of a Sepsis Chart and Its Effects on Mortality Rate in Indonesian Primary Referral Hospitals

An observational study in Sepsis and Antimicrobial Resistance (AMR), sponsored by Dr Cipto Mangunkusumo General Hospital. Recruiting at 2 sites in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Dr Cipto Mangunkusumo General Hospital · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Sep 28, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
304
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the effectiveness of implementing Koran Sepsis, or sepsis chart, a paper-based order set designed to guide the implementation of the One-hour Sepsis Bundle, in improving adherence to early sepsis management and reducing 7-day mortality among adult patients with sepsis presenting to the Emergency Department. The main questions it aims to answer are:

  1. Does implementation of a sepsis chart improve adherence to the One-hour Sepsis Bundle among adult patients with sepsis?
  2. Does implementation of a sepsis chart reduce 7-day mortality among adult patients with sepsis?

Researchers will compare the period before and after implementation of Koran Sepsis to determine whether its implementation improves adherence to the One-hour Sepsis Bundle and reduces 7-day mortality.

Participants will:

  • Receive standard clinical care for sepsis, with management documented during the first hour after sepsis is suspected or diagnosed.
  • Receive care guided by sepsis chart after its implementation at the participating hospital.
  • Have clinical data collected from their medical records, including adherence to the One-hour Sepsis Bundle and time to administration of broad-spectrum antibiotics.
  • Be followed for seven days to determine their mortality outcome.

The study will include adult patients aged ≥18 years diagnosed with sepsis according to the Sepsis-3 definition who present to the Emergency Department and are admitted to one of two participating hospitals: Cipto Mangunkusumo and Fatmawati General Hospital.

Read the detailed description

Background

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. If not recognized and treated promptly, sepsis may progress to septic shock, resulting in multiple organ failure and death. Sepsis is a serious complication of infectious diseases and remains one of the leading causes of death worldwide, particularly in low- and middle-income countries.

Globally, an estimated 48.9 million cases of sepsis occurred in 2017, with approximately 11 million sepsis-related deaths, accounting for 19.7% of all global deaths. Data from 16 Asian countries reported an intensive care unit mortality rate of 44.5% among patients with sepsis. At Dr. Cipto Mangunkusumo National Referral Hospital (RSCM), a 2017 study reported that 64% of adult patients with infection had sepsis, defined as a Sequential Organ Failure Assessment (SOFA) score >2. Another study conducted between 2016 and 2022 reported a mortality rate of 69% among patients with sepsis at RSCM, with a higher risk of mortality among patients with metabolic comorbidities. Data from the Community Services Coordinator of the Department of Internal Medicine at RSCM also showed that 10.3% of internal medicine inpatients were diagnosed with sepsis.

The One-hour Sepsis Bundle is a set of interventions recommended to be initiated within the first hour of suspected sepsis. These interventions include measurement of serum lactate, collection of blood cultures, administration of broad-spectrum antibiotics, fluid resuscitation, and hemodynamic management, with the aim of improving tissue perfusion and achieving early infection control.

Although several studies have demonstrated the effectiveness of the One-hour Sepsis Bundle in reducing mortality, its implementation at RSCM has not been systematically evaluated. Currently, there is no specific sepsis scoring system integrated into the Hospital Information System (HIS) or clinical pathway for patients with sepsis. In addition, a review by the Medical Committee indicated that the One-hour Sepsis Bundle had not been implemented in the majority of sepsis cases presenting to the Emergency Department (ED).

Previous studies have demonstrated that the use of sepsis forms and implementation of sepsis codes may reduce mortality and length of hospital stay. One approach to improving implementation is Koran Sepsis, a paper-based order set designed to guide healthcare professionals in delivering the One-hour Sepsis Bundle. This study aims to evaluate the effectiveness of Koran Sepsis implementation on short-term mortality, defined as 7-day mortality, among patients with sepsis at during the period of September 2026 - 2027

Objectives

The primary objective of this study is to evaluate the effectiveness of Koran Sepsis implementation in improving adherence to the One-hour Sepsis Bundle and reducing 7-day mortality among patients with sepsis.

Specifically, this study aims to determine the proportion of patients receiving initial sepsis management according to the One-hour Sepsis Bundle prior to Koran Sepsis implementation and to determine the proportion of healthcare professionals adhering to the One-hour Sepsis Bundle following its implementation. The study will also compare adherence to the One-hour Sepsis Bundle before and after Koran Sepsis implementation and assess differences in 7-day mortality between the two periods.

In addition, this study aims to evaluate the association between individual components of the One-hour Sepsis Bundle, including serum lactate measurement, blood culture collection, administration of broad-spectrum antibiotics, fluid administration, and vasopressor administration, and 7-day mortality among patients with sepsis.

Study Design

This study is an observational study using a pragmatic stepped-wedge cluster design. The participating hospitals will transition sequentially from the standard-of-care period to the sepsis chart implementation period. The sequence of hospital implementation will be determined according to the order in which approval are obtained.

Sample Size Calculation

Based on the estimated number of participating hospitals, the number of steps in the stepped-wedge design, and the anticipated difference in proportions, the sample size was calculated using the formula proposed by Hemming et al., resulting in a total sample size of 304 patients from 2 hospitals.

Study Procedures and Data Collection

Patients meeting the operational definition of sepsis will be recruited consecutively during the study period. Their clinical management during the initial hour of sepsis care will be documented, including the implementation of each component of the One-hour Sepsis Bundle. Patients will subsequently be followed for seven days to determine their mortality outcome.

Data will be collected using a case report form completed by clinicians or trained research personnel based on information obtained from the patients' medical records. Information regarding sepsis management will be obtained from the electronic health record and Koran Sepsis documentation. All collected data will be processed anonymously to maintain patient confidentiality.

Study Variables and Parameters

The primary outcome of this study is 7-day mortality, defined as death occurring during hospitalization within seven days following admission.

Secondary outcomes include adherence to the One-hour Sepsis Bundle and the time to administration of broad-spectrum antibiotics. We will assess adherence to the One-hour Sepsis Bundle based on documentation of the relevant interventions in the electronic health record and Koran Sepsis. The components assessed will include serum lactate measurement, blood culture collection before antibiotic administration, administration of broad-spectrum antibiotics, administration of 30 mL/kg crystalloid fluid, and vasopressor administration when fluid resuscitation is inadequate or unsuccessful. The time to administration of broad-spectrum antibiotics will be defined as the time elapsed between sepsis diagnosis and antibiotic administration.

Patient-level characteristics that will be collected include age, sex, Charlson Comorbidity Index (CCI), lactate-modified qSOFA score, SOFA score, presence of septic shock, source of infection, and identified pathogen. Age will be categorized as 18-59 years and ≥60 years. The CCI will be calculated based on the patient's documented comorbidities and subsequently categorized as high or low according to the optimal cut-off derived from receiver operating characteristic (ROC) curve analysis. The lactate-modified qSOFA score will be determined based on clinical and laboratory parameters and categorized as high or low according to the cut-off derived from ROC curve analysis.

Hospital-level characteristics will also be collected to account for potential differences between participating centers. These variables will include the total number of inpatient admissions per month, total number of ED visits per month, number of inpatient beds, and the types of pathogens commonly identified at each hospital.

The primary exposure of interest is the implementation of Koran Sepsis. The primary clinical outcome is 7-day mortality. Adherence to the One-hour Sepsis Bundle will be evaluated as an implementation-related outcome and will also be assessed in relation to mortality. Potential confounding variables will include patient-level characteristics and hospital-level factors.

Data and Statistical Analysis

Data will undergo data entry, editing, coding, processing, and cleaning. Data quality will be assessed by identifying missing values, inconsistencies, and implausible variations before statistical analysis.

Statistical analyses will be performed using STATA version 15.1. Numerical variables will be presented as mean ± standard deviation (SD) for normally distributed data or as appropriate measures of central tendency and dispersion when the data are not normally distributed. Categorical variables will be presented as frequencies and percentages.

The primary and secondary outcomes will be analyzed using multilevel regression models to account for the clustering of observations within participating hospitals. The analysis will incorporate hospital-level random effects to account for between-hospital variability and intracluster correlation. The stepped-wedge design will also be taken into consideration in the analysis by accounting for the study period and intervention status.

This approach is intended to control for differences between participating hospitals and minimize potential bias arising from correlation among patients treated within the same hospital. Multivariable analysis will additionally be performed to adjust for relevant patient-level and hospital-level covariates. The association between individual components of the One-hour Sepsis Bundle and 7-day mortality will also be assessed. Relative risks will be calculated to compare mortality between patients who received management consistent with the One-hour Sepsis Bundle and those who did not.

Benefits

This study is expected to contribute to improving the quality of sepsis care at major hospitals in Indonesia by providing evidence regarding the implementation of the One-hour Sepsis Bundle in routine clinical practice.

The study may also identify specific aspects of early sepsis management that can be optimized to reduce mortality among patients with sepsis. Furthermore, the findings are expected to provide scientific evidence regarding the effectiveness of the One-hour Sepsis Bundle and Koran Sepsis, which may support the development of an effective and efficient system for the implementation of standardized sepsis management at participating hospitals.

02

Conditions studied

  • Sepsis
  • Antimicrobial Resistance (AMR)

Browse trials for

Keywords

  • sepsis
  • one-hour sepsis bundle
03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's planned enrollment of 304 is above the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Dr Cipto Mangunkusumo General Hospital is the lead sponsor of 37 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients above ≥18 years diagnosed with sepsis in the emergency department in Cipto Mangunkusumo and Fatmawati General Hospital.

Inclusion criteria

  • Adult patients aged ≥18 years.
  • Patients diagnosed with sepsis according to the Sepsis-3 definition, using the lactate-modified qSOFA score as a reference.
  • Patients presenting to the Emergency Department.
  • Patients who are subsequently admitted to one of the participating hospitals: Cipto Mangunkusumo and Fatmawati General Hospital.

Exclusion criteria

Exclusion Criteria:

  • Incomplete clinical or outcome data required for the study analysis.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
304 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sepsis patients

    All patients included in the study, diagnosed with sepsis according to the sepsis-3 criteria

    Other: Sepsis chart (koran sepsis) · Other: Usual care

Interventions

  • OtherSepsis chart (koran sepsis)

    Implementation of the sepsis one-hour bundle using a paper-based chart containing instructions for the recommended bundle components.

  • OtherUsual care

    Standard sepsis management according to existing hospital practice without implementation of the study-specific sepsis one-hour bundle order set.

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    All death attributed to any reason during study follow-up

    Time frame: 7 days

Secondary outcomes

  1. Time to serum lactate measurement

    Time to serum lactate measurement to identify adherence to the sepsis one-hour bundle, as documented using the paper-based order set containing instructions for the sepsis one-hour bundle.

    Time frame: Within 1 hour after sepsis diagnosis

  2. Time to Administration of Broad-Spectrum Antibiotics

    Time from sepsis diagnosis to administration of broad-spectrum antibiotics, based on documentation of patient management in the electronic health record (EHR) and sepsis record.

    Time frame: Within 24 hours after study inclusion

  3. Time to blood culture collection

    Time to blood culture collection to identify adherence to the sepsis one-hour bundle, as documented using the paper-based order set containing instructions for the sepsis one-hour bundle.

    Time frame: Within 1 hour after sepsis diagnosis

  4. Time to administration of 30 mL/kg crystalloid fluid

    Time to fluid administration to identify adherence to the sepsis one-hour bundle, as documented using the paper-based order set containing instructions for the sepsis one-hour bundle.

    Time frame: Within 1 hour after sepsis diagnosis

  5. Vasopressor administration

    Identify whether any vasopressor is administered as needed.

    Time frame: Within 24 hour after sepsis diagnosis

07

Study locations

1 of 2 sites recruiting
  • Dr Cipto Mangunkusumo General Hospital
    Jakarta Pusat, DKI Jakarta 10430, Indonesia
    Recruiting
  • Fatmawati General Hospital
    Jakarta Pusat, DKI Jakarta 10430, Indonesia
    Not yet recruiting
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07843277
Lead sponsor
Dr Cipto Mangunkusumo General Hospital
Responsible party
Robert Sinto (Principal Investigator, Dr Cipto Mangunkusumo General Hospital) — Principal investigator
First posted
Sep 28, 2026
Start date
Sep 1, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Sharifah Shakinah, MD
Contact
sharifah.shakinah@gmail.com
+628129670607

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion